Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

Heart attacks in women: Women with non-ST-segment elevation acute coronary syndrome (NSTE ACS) benefit as much as men from coronary intervention, according to a meta-analysis of eight randomized clinical trials including 3,075 women and 7,075 men. Results of the study, led by Michelle O'Donoghue, Brigham and Women's Hospital in Boston, appear in the July 2 Journal of the American Medical Association. The eight trials, conducted between 1970 and 2008, compared invasive treatment to conservative therapy of NSTE ACS and collected sex-specific data on death, myocardial infarction and rehospitalization for at least 12 months of follow-up. Among women with biomarkers showing they are at high risk for myocardial infarction, an invasive therapy reduced the risk of death, myocardial infarction or acute coronary syndrome by 33%. The invasive strategy was not associated with better outcomes in women without the biomarker for high risk
Advertisement

Related Content

Earnings Calls In Brief
Earnings Calls In Brief
New Label For Evicel Fibrin Sealant Could Boost Omrix/Ethicon Market Share
New Label For Evicel Fibrin Sealant Could Boost Omrix/Ethicon Market Share
Advertisement
UsernamePublicRestriction

Register

MT026307

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel